Back to News
Market Impact: 0.3

After-Hours Earnings Report for September 23, 2025 : MU, WOR, AIR, MLKN, AYTU

MUWORAIRMLKNAYTUNDAQ
Corporate EarningsAnalyst EstimatesCompany FundamentalsTechnology & InnovationHealthcare & BiotechInfrastructure & Defense
After-Hours Earnings Report for September 23, 2025 :  MU, WOR, AIR, MLKN, AYTU

Several companies are set to report earnings on September 23, 2025, with Micron Technology (MU) projecting a substantial 169.70% year-over-year EPS increase to $2.67, having consistently beaten estimates with a P/E below its industry average. AAR Corp. (AIR) also demonstrates strength, expecting a 15.29% EPS rise and trading at a significantly lower 17.36 P/E compared to its industry's 57.60. In contrast, MillerKnoll (MLKN) anticipates a 2.78% EPS decrease following a recent miss, while Worthington Enterprises (WOR) forecasts a 60% EPS increase and Aytu BioPharma (AYTU) expects a 97.56% improvement in its negative EPS.

Analysis

An upcoming slate of earnings reports highlights divergent outlooks across several sectors. Micron Technology (MU) stands out with a consensus EPS forecast of $2.67, representing a formidable 169.70% year-over-year increase, supported by a consistent track record of beating analyst expectations over the past year. Its 2025 P/E ratio of 22.43 sits below the industry average of 25.00, suggesting a potentially favorable valuation relative to its growth profile. Similarly, AAR Corp. (AIR) is positioned for a solid 15.29% YoY EPS increase to $0.98, has also consistently surpassed estimates, and trades at a significant valuation discount with a 2026 P/E of 17.36 compared to the aerospace industry's 57.60. In contrast, MillerKnoll (MLKN) faces headwinds, with analysts forecasting a 2.78% YoY EPS decline to $0.35, compounded by a -14.29% earnings miss in a recent quarter and a high 2026 P/E of 10.99 versus its industry's 4.90. Other firms present a mixed picture; Worthington Enterprises (WOR) expects strong 60.00% EPS growth, but its 2026 P/E of 16.72 is at a premium to its industry's 14.30. Aytu BioPharma (AYTU) shows a significant 97.56% improvement in its EPS forecast to $-0.02, but remains unprofitable with a negative P/E of -9.58. The sparse analyst coverage for WOR and AYTU (one analyst each) adds a layer of uncertainty to their forecasts.

AllMind AI Terminal